Written by Julia Rostova
A deep-dive analysis of the telehealth platform navigating regulatory upheaval, a transformative Novo Nordisk partnership, and a massive peptide opportunity the market is pricing at zero.
Equities Orbis | June 15, 2026
The telehealth landscape is undergoing a brutal sorting process, separating platforms that merely dispense pills from those building durable, verticalized healthcare infrastructure. Hims & Hers Health (HIMS) sits at the epicenter of this transformation. After a tumultuous first quarter marked by regulatory scrutiny, a dramatic pivot away from compounded GLP-1s, and a GAAP net loss that spooked retail investors, the stock has plummeted nearly 60% from its July 2025 highs to hover around $28 per share. Yet, beneath the headline noise of a $92 million GAAP loss lies a company with $751 million in cash, accelerating subscriber growth, and a massive regulatory catalyst looming in July 2026. For inflection traders seeking mispriced assets with significant momentum potential, HIMS presents a compelling, albeit volatile, setup.
The Financial Reality Behind the GAAP Noise
The market’s reaction to Hims & Hers’ Q1 2026 earnings was swift and punishing, driven largely by a GAAP net loss of $92 million—the first unprofitability since Q4 2023. However, a forensic examination of the balance sheet reveals a fortress underlying the accounting anomalies. The loss was heavily influenced by approximately $33 million in restructuring charges, specifically $28 million in write-downs related to the abandonment of their compounded GLP-1 supply chain. Additional non-cash items included $17.6 million in contingent consideration adjustments from acquisitions performing above expectations, $13.4 million in M&A costs from the Eucalyptus and ZAVA integrations, and $9.7 million in unrealized investment losses.
Revenue for the quarter reached $608 million, a modest 4% year-over-year increase that technically missed consensus estimates by $8.75 million. But this deceleration is an optical illusion caused by revenue recognition timing. By shifting from upfront compounded sales to a monthly branded subscription model, HIMS deferred approximately $65 million in revenue. Adjusted for this transition, comparable revenue growth would have been closer to 15%. Furthermore, international revenue exploded by 969% to $78 million, bolstered by the recent Eucalyptus acquisition which brings 550,000 customers across Australia, Japan, Germany, and Canada into the ecosystem.
Valuation metrics suggest the market is pricing in peak execution risk while ignoring the platform’s cash generation. HIMS trades at a forward non-GAAP P/E of 13.87 and an EV/Sales multiple of 2.78. The EV/EBITDA ratio, currently compressed between 78x and 85x due to the restructuring, obscures the company’s free cash flow generation, which stood at a healthy $53 million for the quarter. Management raised FY2026 revenue guidance to a range of $2.8 billion to $3.0 billion, projecting adjusted EBITDA between $275 million and $350 million. The company’s 2030 target remains a formidable $6.5 billion in revenue with $1.3 billion in adjusted EBITDA.
| Metric | Q1 2026 Actual | YoY Change / Note |
| Revenue | $608 Million | +4% (Optical miss due to transition) |
| Subscribers | 2.58 Million | +9% YoY |
| Free Cash Flow | $53 Million | Strong liquidity generation |
| Adjusted EBITDA | $44 Million | 7% Margin (Restructuring impact) |
| Forward P/E (Non-GAAP) | 13.87x | Deep value for a growth platform |
The GLP-1 Pivot and the Novo Nordisk Alliance
The most critical narrative shift for HIMS occurred in March 2026, when the company abruptly ceased advertising compounded GLP-1 medications following intense scrutiny from the FDA, DOJ, and SEC over a short-lived $49 compounded pill. Instead, HIMS executed a strategic masterstroke: partnering directly with Novo Nordisk to distribute branded Wegovy through its platform.
This pivot immediately de-risked the regulatory profile while accelerating growth. Within six weeks of the partnership, HIMS fulfilled over 125,000 Wegovy shipments, establishing a run rate of more than 100,000 new weight-loss subscribers per month. While the branded product carries a lower gross margin than compounded alternatives, the higher price point ($149/month after an initial $39 introductory offer) makes the unit economics roughly comparable. The primary risk here is churn—whether consumers will tolerate the price step-up—but early engagement metrics, including nearly 90% app download rates and an average of three clinician consultations in the first month, suggest strong retention potential. In Canada, HIMS has simultaneously launched generic semaglutide at C$149/month following Novo Nordisk’s patent expiration, undercutting all competitors in that market.
Verdict on Novo Nordisk (NVO): HOLD. Price Target: $49.50. Novo Nordisk remains the undisputed king of the GLP-1 space, but its valuation appears stretched. Trading near $47, the stock sits just below consensus targets, reflecting limited near-term upside. While the HIMS partnership expands their distribution moat, capacity constraints and intensifying competition from Eli Lilly limit the potential for massive multiple expansion.
The Regulatory Catalyst: The $20 Billion Peptide Bet
While the market fixates on the GLP-1 transition, it is entirely ignoring the impending FDA Pharmacy Compounding Advisory Committee panel scheduled for July 23–24, 2026. The panel will review 12 compounded peptides, including BPC-157, TB-500, and Semax. HIMS has quietly built a massive infrastructure advantage, acquiring a U.S.-based peptide manufacturing facility in 2025 and maintaining a 503A compounding footprint exceeding one million square feet. Canaccord Genuity estimates the compounded peptide total addressable market (excluding GLP-1s) could reach $20 billion over the next three to five years. Every 1% of market share captured equates to roughly $200 million in incremental revenue for HIMS. If the FDA ruling provides regulatory clarity, HIMS is perfectly positioned to dominate a highly lucrative, high-margin category that is currently assigned zero value in the stock price.
Competitive Positioning in a Crowded Market
The telehealth and weight-loss landscape is brutally competitive, but HIMS is demonstrating structural advantages over its peers.
WeightWatchers (WW): SELL. Price Target: $12.00. WeightWatchers has been decimated, with shares down 45.5% year-to-date to roughly $17. Despite integrating GLP-1 care through a partnership with LillyDirect, the legacy brand is struggling to adapt. Q1 2026 revealed a $52 million net loss on just $168 million in revenue. The company is burdened by debt and faces a very high uncertainty rating from Morningstar. The pivot to clinical weight loss feels defensive rather than offensive, and the brand lacks the technological infrastructure to compete with purpose-built telehealth platforms.
Eli Lilly (LLY): BUY. Price Target: $1,250.00. Trading near $1,021, Eli Lilly justifies its premium valuation (29x forward P/E) through sheer growth, guiding for 28% revenue expansion and 50% EPS growth in 2026. The LillyDirect platform bypasses traditional telehealth middlemen, allowing the manufacturer to capture maximum margin. The pipeline depth beyond Zepbound ensures LLY remains the ultimate momentum play in mega-cap pharma. Bank of America’s $1,251 target reflects the dominant obesity drug positioning.
Ro (Roman Health): HOLD. Private Valuation Target: $6.00/share. As a direct competitor to HIMS, Ro has built an impressive direct-to-patient infrastructure with estimated private market pricing around $5.29 to $7.07 per share. However, they lack the public market currency to aggressively acquire and face similar compounding regulatory risks without the massive scale of the HIMS platform. The pre-IPO stage limits visibility into their financials.
Noom: SELL (Private). Noom’s behavioral coaching model is rapidly losing relevance in the GLP-1 era. While they offer medication access ranging from $60 to $150 monthly for the app plus medication costs, consumers are increasingly favoring platforms that prioritize seamless pharmaceutical access over gamified psychology. Their transition to clinical care appears too slow to capture meaningful market share.
The Bull and Bear Cases for HIMS
The Bull Case: HIMS successfully navigates the transition to branded GLP-1s, maintaining the 100,000+ monthly subscriber run rate without massive churn from the price step-up. The July FDA panel legitimizes the peptide market, allowing HIMS to leverage its one million square foot compounding infrastructure to capture a massive new revenue stream. The Eucalyptus acquisition scales international revenue, driving adjusted EBITDA past $300 million for FY2026. The stock re-rates from a distressed multiple back toward its historical average, easily eclipsing $40.
The Bear Case: The $149/month price point for branded Wegovy proves too steep, resulting in catastrophic churn after the introductory period. The FDA takes a hardline stance against compounded peptides in July, rendering the 2025 manufacturing acquisition a stranded asset. The partnership with Novo Nordisk fractures over pricing or distribution disputes, leaving HIMS without a reliable GLP-1 supply. The high short interest (31.4% of float) and elevated beta (2.43) accelerate downside momentum, pushing the stock back toward its 52-week lows near $14.
The Verdict
Hims & Hers Health is executing a textbook inflection pivot. Management has aggressively de-risked the business by abandoning legally dubious compounded GLP-1s in favor of a legitimate partnership with Novo Nordisk, while simultaneously expanding internationally and preparing for a massive peptide opportunity. The GAAP losses are optical, driven by restructuring rather than operational failure. With a fortress balance sheet, accelerating subscriber growth, and significant insider buying—Board member David Wells recently purchased 48,400 shares at $24.24—the risk/reward asymmetry is highly favorable.
Verdict on Hims & Hers Health (HIMS): BUY. Price Target: $39.00. The current valuation of $28 prices in execution failure while ignoring the $20 billion peptide option and the cash-generating power of the core platform. Patient capital should accumulate shares ahead of the July FDA catalyst and the anticipated back-half EBITDA step-up.
Ratings Summary
| Stock | Rating | Price Target |
| Hims & Hers Health (HIMS) | BUY | $39.00 |
| Novo Nordisk (NVO) | HOLD | $49.50 |
| Eli Lilly (LLY) | BUY | $1,250.00 |
| WeightWatchers (WW) | SELL | $12.00 |
| Ro (Private) / Noom (Private) | HOLD / SELL | $6.00 / N/A |
